New study tracks joint health in IBD patients on guselkumab
NCT ID NCT07602517
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study will follow 75 adults aged 18-75 with Crohn's disease or ulcerative colitis who are starting guselkumab treatment. The goal is to see how the drug affects joint pain and stiffness related to spondyloarthritis over one year. Participants will report their symptoms through questionnaires, and researchers will also measure inflammation levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPONDYLOARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.